Novel strain of lactobacillus rhamnosus and its metabolites for use in inhibiting xanthine oxidase and treating gout

Abstract

A method for inhibiting xanthine oxidase and for reducing uric acid levels using a composition obtained by culturing Lactobacillus rhamnosus in a medium. Also disclosed is a composition including a metabolite of Lactobacillus rhamnosus for reducing uric acid levels in a subject and a method for producing the composition.

1 . A composition for reducing uric acid levels in a subject, the composition comprising a metabolite of  Lactobacillus rhamnosus  mixed with a pharmaceutically acceptable carrier selected from the group consisting of ethylenediamine tetraacetic acid, dimethyl sulfoxide, polyvinyl-pyrrolidone, polyvinyl alcohol, polyethylene glycol, and a combination thereof, wherein the metabolite is an inhibitor of xanthine oxidase activity and the  Lactobacillus rhamnosus  is  Lactobacillus rhamnosus  strain I21 deposited under Accession No. DSM 28876. 
     
     
         2 . The composition of  claim 1 , wherein the composition is free of  Lactobacillus rhamnosus.    
     
     
         3 . The composition of  claim 2 , wherein the composition is sterile. 
     
     
         4 . The composition of  claim 1 , wherein the composition is sterile. 
     
     
         5 . The composition of  claim 1 , further comprising a probiotic microorganism selected from the group consisting of  Lactobacillus  spp.,  Bifidobacterium  spp.,  Saccharomyces  spp, and a combination thereof. 
     
     
         6 . The composition of  claim 5 , wherein the probiotic microorganism is one or more of  Lactobacillus fermentum, Lactobacillus pentosus, Lactobacillus gasseri, Lactobacillus oris, Bifidobacterium longum,  and  Saccharomyces cerevisiae.    
     
     
         7 . The composition of  claim 2 , further comprising a probiotic microorganism selected from the group consisting of  Lactobacillus  spp.,  Bifidobacterium  spp.,  Saccharomyces  spp, and a combination thereof. 
     
     
         8 . The composition of  claim 7 , wherein the probiotic microorganism is one or more of  Lactobacillus fermentum, Lactobacillus pentosus, Lactobacillus gasseri, Lactobacillus oris, Bifidobacterium longum,  and  Saccharomyces cerevisiae.    
     
     
         9 . The composition of  claim 1 , wherein the composition is a liquid solution, a suspension, an emulsion, a syrup, a tablet, a pill, a capsule, a sustained release formulation, a powder, a granule, an ointment, a lotion, a liniment, or a cream. 
     
     
         10 . The composition of  claim 2 , wherein the composition is a liquid solution, a suspension, an emulsion, a syrup, a tablet, a pill, a capsule, a sustained release formulation, a powder, a granule, an ointment, a lotion, a liniment, or a cream. 
     
     
         11 . A composition for reducing uric acid levels in a subject, the composition comprising a culture of  Lactobacillus rhamnosus  mixed with a pharmaceutically is acceptable carrier selected from the group consisting of ethylenediamine tetraacetic acid, dimethyl sulfoxide, polyvinyl-pyrrolidone, polyvinyl alcohol, polyethylene glycol, and a combination thereof, wherein the composition is an inhibitor of xanthine oxidase activity and the  Lactobacillus rhamnosus  is  Lactobacillus rhamnosus  strain I21 deposited under Accession No. DSM 28876. 
     
     
         12 . The composition of  claim 11 , wherein the composition is a liquid solution, a suspension, an emulsion, a syrup, a tablet, a pill, a capsule, a sustained release formulation, a powder, a granule, an ointment, a lotion, a liniment, or a cream. 
     
     
         13 . The composition of  claim 12 , wherein the composition is sterile. 
     
     
         14 . The composition of  claim 11 , wherein the composition is sterile. 
     
     
         15 . The composition of  claim 11 , further comprising a probiotic microorganism selected from the group consisting of  Lactobacillus  spp.,  Bifidobacterium  spp.,  Saccharomyces  spp, and a combination thereof. 
     
     
         16 . The composition of  claim 15 , wherein the probiotic microorganism is one or more of  Lactobacillus fermentum, Lactobacillus pentosus, Lactobacillus gasseri, Lactobacillus oris, Bifidobacterium longum,  and  Saccharomyces cerevisiae.    
     
     
         17 . The composition of  claim 12 , further comprising a probiotic io microorganism selected from the group consisting of  Lactobacillus  spp.,  Bifidobacterium  spp.,  Saccharomyces  spp, and a combination thereof. 
     
     
         18 . The composition of  claim 17 , wherein the probiotic microorganism is one or more of  Lactobacillus fermentum, Lactobacillus pentosus, Lactobacillus gasseri, Lactobacillus oris, Bifidobacterium longum,  and  Saccharomyces cerevisiae.    
     
     
         19 . The composition of  claim 11 , wherein the culture of  Lactobacillus rhamnosus  includes a culture medium selected from de Man-Rogosa Sharpe broth, milk, and juice. 
     
     
         20 . The composition of  claim 11 , further comprising one or more food ingredient selected from the group consisting of a colorant, an acidity regulator, an anticaking agent, an antioxidant, a bulking agent, a carrier, an emulsifier, a flavor enhancer, a glazing agent, a preservative, a stabilizer, a sweetener, a thickener, a nutrient additive, a flavoring agent, and a combination thereof.